OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Testing resistance at 20p, needs more volumes to get through that and then it's 23 then 25.

Where next?

Back to 30 I hope.

Lots of small caps seem to be recovering.

Time to buy again, more news to come soon and these will motor again, there's hardly any risk buying at 16p - the foundations have been laid and the fair value is nearer 35p, the graph shows 16 as the resistance and that level will rise with added value from license deals and positive newsflow, this share really is undervalued at this price. Still confident 2 in next 3yrs.

robstuff

Yep, it is a good time.

The buyers are back today so I joined them.

On the up again!

Hardly moving - boring at 16p

Hello whats brought this on to-day (nicely jumped into the blue) let us hope that there has been a little leak of good news to come.

Intrims and analyst briefing next Wed, good news maybe !

The results will be on web cast too for those who wish to watch

http://www.oxfordbiomedica.co.uk

What a nice rise, I sold out at 18p a while back but bought some again at the end of last month & decided to get back in substantially when it hit 14.5p.

Except for last month, I accidently seem to keep getting my timing just right with OXB :-)

It just might keep going blue prior to next Wednesday if and when good news should see it return to 25p -

Another nice rise today but not a great number of buyers to cause it.

Encouraging interim on Wednesday next week

hlyeo98, have you read it or did you use a crystal ball :-))

You will see, Apple...on Wednesday

Sunday Telegraph
Take a look at Oxford Biomedica (16.25p), the biotechnology company focused on gene therapy. The company is using its patented LentiVector gene technology - a method of injecting genetic material into cells - to develop potential treatments for conditions such as Parkinson's disease and blindness.

The company is working in an area of revolutionary science that is as yet unproven, but if it works it is sitting on a possible goldmine. The potential for strong newsflow over the coming months - it reports interims this Wednesday - should also help drive the share price.
The shares, which are well off the 39.79p high in 2002, are for investors willing to take a risky punt.

39 - 2002, what about 135 - 2000? Have been a long term holder since 98, and just know these will make me seriously rich

UP 9.23% so far today.

OXFORD BIOMEDICA ANNOUNCES POSITIVE INTERIM PHASE II RESULTS WITH TROVAX IN COLORECTAL CANCER

Oxford, UK - 1 September 2004: Oxford BioMedica (LSE: OXB) announced today that the primary endpoints have been achieved at the interim stage of two Phase II trials in patients with Stage IV colorectal cancer receiving TroVax alongside chemotherapy. TroVax is the Company's novel cancer immunotherapy product against the tumour associated antigen 5T4. The primary endpoints are safety and demonstrable anti-tumour immune responses against the 5T4 tumour antigen.

The results from an interim analysis of both trials, initiated in 2003, showed that the combination of TroVax and standard of care chemotherapy is safe and that patients mount specific immune responses to the 5T4 antigen. Full recruitment is imminent across both trials with 36 of 37 projected patients
enrolled. The objective is to have ten evaluable patients in each setting. The interim results are based on 13 patients in total, who have reached an interim analysis point defined as four TroVax immunisations and more than eight cycles
of chemotherapy. There have been no serious adverse events associated with TroVax treatment and the product was well tolerated. 11 of the 13 patients (85%) mounted antibody and/or cellular immune responses to the 5T4 tumour antigen
following four immunisations with TroVax.

The Company expects to report full safety and immunological data in mid-2005 when all patients will have received 12 cycles of chemotherapy and 6 doses of TroVax. At this time, tumour response rates will also be determined.

TroVax plus IFL chemotherapy

The protocol of the first Phase II trial is six immunisations of TroVax alongside chemotherapy cycles of irinotecan, 5-fluorouracil (5FU) and leucovorin (a combination referred to as IFL). A total of 19 patients have been enrolled.
Ten patients have reached the interim analysis point. Nine out of ten patients (or 90%) have mounted specific anti-tumour immunological responses to the 5T4 antigen.

TroVax plus FOLFOX chemotherapy

The second Phase II trial protocol is similarly six immunisations of TroVax alongside cycles of oxaliplatin, 5FU and leucovorin (referred to as FOLFOX). The trial is fully recruited at 17 patients. Three patients have reached the interim
analysis point and two of these (or 67%) have shown anti-5T4 immune responses to date.

Commenting on the Phase II results, Prof. Alan Kingsman, Chief Executive of Oxford BioMedica, said, 'We are very pleased with the progress of our first Phase II trials with TroVax. The high number of anti-5T4 responses at this interim stage suggests that patients are able to mount an anti-tumour immune
response even in the context of chemotherapy treatment. In our earlier Phase I/ II trials, it was clear that anti-5T4 immune responses correlated with improved patient survival. We now feel confident that TroVax has a role to play in the
treatment of colorectal cancer.'


-Ends-